Targeting FLT3 mutations in AML: review of current knowledge and evidence
Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several
genes are recurrently mutated, leading to new genomic classifications, predictive …
genes are recurrently mutated, leading to new genomic classifications, predictive …
[PDF][PDF] An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment
T Grafone, M Palmisano, C Nicci… - Oncology …, 2012 - frontierspartnerships.org
Hematopoiesis, the process by which the hematopoietic stem cells and progenitors
differentiate into blood cells of various lineages, involves complex interactions of …
differentiate into blood cells of various lineages, involves complex interactions of …
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open …
JE Cortes, S Khaled, G Martinelli, AE Perl… - The Lancet …, 2019 - thelancet.com
Background Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-
ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of …
ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of …
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute …
An internal tandem duplication in the fms-like tyrosine kinase 3 gene (FLT3/ITD) is
associated with poor prognosis in acute myeloid leukemia (AML), but the impact of mutant …
associated with poor prognosis in acute myeloid leukemia (AML), but the impact of mutant …
The structural basis for autoinhibition of FLT3 by the juxtamembrane domain
J Griffith, J Black, C Faerman, L Swenson, M Wynn… - Molecular cell, 2004 - cell.com
FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis.
Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that …
Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that …
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute …
D Cilloni, A Renneville, F Hermitte, RK Hills… - Journal of Clinical …, 2009 - ascopubs.org
Purpose Risk stratification in acute myeloid leukemia (AML) is currently based on
pretreatment characteristics. It remains to be established whether relapse risk can be better …
pretreatment characteristics. It remains to be established whether relapse risk can be better …
Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia
M Sakaguchi, H Yamaguchi, Y Najima, K Usuki… - Blood …, 2018 - ashpublications.org
In the opinion of the European LeukemiaNet (ELN), nucleophosmin member 1 gene
mutation (NPM1 mut)–positive acute myeloid leukemia (AML) with an fms-like kinase 3 …
mutation (NPM1 mut)–positive acute myeloid leukemia (AML) with an fms-like kinase 3 …
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
N Boissel, H Leroy, B Brethon, N Philippe, S De Botton… - Leukemia, 2006 - nature.com
In core binding factors (CBF) acute myeloid leukemia (AML), the disruption of CBFα/β genes
impairs normal hematopoietic differentiation and is supposed to cooperate with additional …
impairs normal hematopoietic differentiation and is supposed to cooperate with additional …
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in …
The prognostic impact of tyrosine kinase domain (TKD) mutations of the fms-like tyrosine
kinase-3 (FLT3) gene in acute myeloid leukemia (AML) is currently uncertain. To resolve this …
kinase-3 (FLT3) gene in acute myeloid leukemia (AML) is currently uncertain. To resolve this …
Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies
HA Hou, HF Tien - Journal of biomedical science, 2020 - Springer
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …